New York, USA – On this coming Thanksgiving, Creative Biolabs, a leading service provider, offers 10% off discount for all Antibody-drug Conjugates Products to share the genuine appreciation with both academic and industrial clients all over the world.
As a potent therapeutic drug consisting of a monoclonal antibody, a toxic payload, and a chemical linker, antibody-drug conjugate has earned it a place in the competitive immunotherapy field owing to high selectivity, less side effect and a solid methodology. With the purpose to thank the continuous support from regular clients and to share holiday blessings with future clients, Creative Biolabs offers 10% off antibody-drug conjugates (ADCs) products, valid until November 30, 2019.
Based an advanced “DrugLnk” service platform for customary synthesis of drug-linker complexes for ADC development projects, Creative Biolabs is capable of preparing a large collection of the chemical building blocks for ADCs, including a full list of ADC toxins, linkers, and already synthesized drug-linker complexes, featured by high purity (>95%) and wide availability at different quantities. Both milligram-grade for R&D purposes and gram-grade for GMP-scale preparations are provided.
Aiming to help clients save time and cost for the ADC development projects, Creative Biolabs not only offers highly potent toxins and toxin derivatives targeting a wide variety of cellular pathways, including microtubule assemble and dynamics (microtubule toxins), DNA biochemistry and structure (DNA toxins), and gene transcription (transcription toxins), but also provides a large selection of ADC toxins ranging from common auristatins, maytansinoids, calicheamicins to more innovative toxins such as amatoxins, with defined structure as often characterized by LC-MS and 1HNMR.
As basic building blocks for a successful ADC, a variety of chemically versatile ADC linker molecules from Creative Biolabs can facilitate the conjugation of ADC toxins to antibodies and dictate the release mechanism of an ADC. In order to ease the process of obtaining the conjugate and enhance the chemical and serum stability of the ADC, Creative Biolabs offers a series of cleavable linkers (pH-sensitive linkers, disulfide linkers, peptide linkers, ß-glucuronide linkers), non-cleavable linkers, and intermediate linker modules.
In addition, a large collection of pre-assembled drug-linker complexes are available at Creative Biolabs for ready-to-go antibody conjugation to accelerate novel antibody-drug conjugate (ADC) development processes, ranging from well-established compounds such as MC-vc-PAB-MMAE, SMCC/sulfo-SMCC-maytansinoid derivatives to more innovative complex sets including peptide linker-based duocarmycin derivative, pH labile linker-based calicheamicin set, which are chemically well-defined using LC-MS and 1HNMR spectroscopy.
“In the past 10 years, we have served numerous academic and industrial clients to help with different ADC projects. In order to express our appreciation, we offer 10% discount covering all antibody-drug conjugates to celebrate this Thanksgiving. We wish our clients surrounded with love and happiness,” said the manager at Creative Biolabs.
More information for Thanksgiving promotion can be reached at https://www.creative-biolabs.com/adc.
About Creative Biolabs
With more than a decade of exploration and expansion, Creative Biolabs provides current research and service capacity that covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, Creative Biolabs established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. They offer customers comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation.